KAYA17 is a point-of-care testing developer that has developed a solution for the quick and timely diagnosis of the SARS-CoV-2 virus and is also developing rapid anti-body tests for COVID-19 which can evaluate immunity levels in person’s who have received a vaccination. Additionally, rapid tests for other medical conditions such as tests for allergens, certain cancers, infectious diseases such as dengue fever, and other mutations of the SARS virus, will be created by KAYA17.